Texas Biomedical Research Institute

Scientists at Texas Biomed establish a human transgenic mouse model susceptible to SARS-CoV-2 infection

Study provides research community with critical small animal model necessary for researchers developing therapies and vaccines

Newswise — SAN ANTONIO, TEXAS (July 23, 2020) Texas Biomedical Research Institute (Texas Biomed) scientists have added another tool to the COVID-19 toolbelt, validating a new small animal model for studying SARS-CoV-2, the virus that causes COVID-19. Publishing their results preliminarily on the open source journal BioRxiv, researchers at Texas Biomed were among a limited group of scientists nationwide given early access to newly developed transgenic mice that express the human angiotensin-converting enzyme 2 (hACE2) to test whether these mice can be used as a small animal model to assess SARS-CoV-2 infection. Key goals of this study were to determine whether these mice: 1. Can be infected, 2. Reach a similar COVID-19 mortality endpoint as seen in humans with severe COVID-19 disease and 3. Develop immune responses associated with SARS-CoV-2 infection. The paper title is "Lethality of SARS-SoV-2 infection in K18 human angiotensin converting enzyme 2 transgenic mice."

Researchers at Texas Biomed not only found that the human transgenic mice serve as a good model for SARS-CoV-2 infection but also discovered key indicators of an inflammatory immune response (activation of the immune system). Texas Biomed researchers were among the first to discover that this transgenic mouse succumbs to infection, which are critical learnings for future studies. By having a small animal model that mimics a highly susceptible form of human COVID-19 disease, scientists now have the means to perform rapid screening of drug and vaccine candidates and further evaluate SARS-CoV-2 infection progression (pathogenicity). This new tool will play a significant role in reducing the current bottleneck of using nonhuman primates for SARS-CoV-2/COVID-19 vaccine and therapeutic testing.

The team at Texas Biomed, led by Dr. Luis Martínez-Sobrido, Dr. Jordi B. Torrelles and Dr. Joanne Turner, showed detection of virus in the nasal passages, lungs and brain of the K18 hACE2 transgenic mice. These mice also showed significant weight loss before becoming too sick to remain in the study.

“The ACE2 protein has been previously identified as a receptor for SARS-CoV-1, and the expression of the human ACE2 protein in mice renders them susceptible to SARS-CoV-2,” explained Dr. Turner, Professor and Vice President for Research at Texas Biomed. “Scientists have not previously had access to mouse models for SARS-CoV-2 infection studies, because typical lab mice are not susceptible to this virus.”

In this study, scientists showed the K18 hACE2 transgenic mice not only succumbed to the infection but showed systemic (multiple organ) infection with significant virus detected in the nasal passages, lungs, and brain – all organs greatly impacted by SARS-CoV-2 in humans. While minor differences in weight fluctuation were noted between male and female mice after infection, the study did not indicate that gender played a major role in SARS-CoV-2 infectivity or disease progression.

The transgenic mice in this study also developed rhinitis (swelling of the mucus membrane in the nose), pneumonia and associated pulmonary inflammation. Each of these are important indications of viral infection relative to SARS-CoV-2. Essential to the development of an animal model for use in viral studies is identifying the amount of viral exposure necessary to see disease progression that is similar to humans, up to and including mortality. This study is the first to identify the amount of virus necessary during an initial exposure for the transgenic mice to develop severe COVID-19 disease.

“Our data are an important step in increasing our ability to understand SARS-CoV-2 infection and COVID-19 disease in humans,” said Dr. Martínez-Sobrido, Professor at Texas Biomed. “Our studies defined the viral infection dose that results in severe COVID-19 disease and replicated many of the symptoms observed in humans who are admitted to the hospital with severe COVID-19 symptoms.”

In addition to establishing the K18 hACE2 transgenic mouse model supplied by The Jackson Laboratory, researchers also found these transgenic mice were the most susceptible to severe COVID-19 disease progression and produced what is known as a chemokine storm.

Chemokines are small molecules secreted by cells to help signal immune cells to the site of an infection. Chemokines work in concert with cytokines, which are also small molecules or proteins that tell immune cells what to do once they reach the site of infection. The chemokine/cytokine process orchestrates the body’s immune response. A chemokine or cytokine storm can cause an overreaction of the body’s immune system and instead of helping, can cause such a strong response that it becomes detrimental. Determining which chemokines are triggered may be important to development of COVID-19 disease treatments.

“People often succumb to their own body’s immune response to a virus, not the virus itself,” Dr. Turner explained. “There are about 50 known chemokines in the body, so finding a way to block receptors to some of these chemokines would reduce the chemokine/cytokine storm, allowing the body to mount an appropriate immune response.”

Studies on SARS-CoV-2 are completed in biosafety level-3 laboratories under strict regulatory protocols approved by Texas Biomed’s Institutional Biosafety Committee and Institutional Animal Care and Use Committee. Texas Biomed most recently completed a multimillion dollar renovation of BSL-3 space to accommodate the work of Institute scientists, as well as federal and commercial contract studies to test therapeutics and vaccines.

“As noted in the paper, small animal models are more manageable, cost-effective and available for researchers, but we have not had access to a viable mouse model for SARS-CoV-2 infection until now,” explained Dr. Torrelles, Professor, Director of the BSL-3 high-containment program, Lead of the Population Health scientific program and Coordinator of the Coronavirus Working Group at Texas Biomed. “While several nonhuman primate models have been identified to aid in testing vaccines and therapeutics, none have reached endpoints similar to those found in these K18 hACE2 transgenic mice. This mouse model, paired with other small animal models, also in development at Texas Biomed, adds another tool in the toolbox to test therapeutics and fill a critical gap in therapeutic development.”

This study was made possible by community philanthropic support, as well as significant personnel resources dedicating their time and efforts during the pandemic.

SARS-CoV-2 has infected more than 14.7 million people worldwide (3.9 million in the United States) and more than 600,000 people (143,000 in the United States) have lost their lives to this new coronavirus, as of mid-July. In addition to these early-stage studies that are aiding scientists worldwide, researchers at Texas Biomed continue to collaborate with scientists and pharmaceutical companies around the world to move therapies and vaccines through preclinical stages and on to human clinical trials.

“The K18 hACE2 transgenic mouse model developed at Texas Biomed represents an excellent tool to identify both prophylactics (vaccines) and therapeutics (antivirals) to combat SARS-CoV-2 infection and associated COVID-19 disease,” Martínez-Sobrido added.

With the Institute’s focus on infectious diseases and dedication to both basic and translational research, Texas Biomed currently has more than two dozen COVID-19-related studies in process and continues to shepherd partnerships that lead to high-quality science. To learn more visit www.txbiomed.org/coronavirus.

 

###

SEE ORIGINAL STUDY



Filters close

Showing results

1120 of 5853
Newswise:Video Embedded virtual-event-for-june-17-11am-edt-covid-19-vaccines-and-male-fertility
VIDEO
Released: 18-Jun-2021 8:55 AM EDT
VIDEO AND TRANSCRIPT AVAILABLE: Vaccines and Male Fertility Event for June 17, 2021
Newswise

This upcoming JAMA-published study examined whether the COVID-19 vaccine impacts male fertility.

Released: 18-Jun-2021 7:05 AM EDT
Teamwork saves lives: COVID-19 hospital network shares key findings to improve care
Michigan Medicine - University of Michigan

Data sharing among 40 Michigan hospitals about the care and outcomes for thousands of inpatients with COVID-19 has led to reduced variation and findings that could inform care anywhere, including approaches for preventing blood clots and reducing overuse of antibiotics, as well as a risk prediction tool.

Released: 18-Jun-2021 7:05 AM EDT
One-third of older Americans delayed health care over COVID concerns
Michigan Medicine - University of Michigan

Nearly one in three Americans between the ages of 50 and 80 put off an in-person appointment for medical care in 2020 because they were worried about exposure to the novel coronavirus, new national poll data show.

Released: 17-Jun-2021 4:15 PM EDT
UNC Researchers Lead Study of Diabetes Treatment of COVID-19 Patients
University of North Carolina School of Medicine

Diabetes is one of the comorbidities most strongly associated with severe COVID-19 in the US, and data from early in the pandemic suggested individuals with type 2 diabetes faced twice the risk of death from COVID-19 and a greater risk of requiring hospitalization and intensive care. A new study shows best treatment options.

Released: 17-Jun-2021 4:10 PM EDT
Vaccination, Previous Infection, Protect Against COVID-19 gamma/P.1 Variant in Animal Model
University of Wisconsin-Madison

In a new study using variant virus recovered from one of the original travelers, researchers in the U.S. and Japan have found that vaccination with an mRNA vaccine induces antibody responses that would protect humans from infection with the gamma/P.1 variant.

Released: 17-Jun-2021 1:30 PM EDT
Hackensack Meridian Doctors, Student Help Establish Way to Prioritize Surgeries During COVID-19 lockdown
Hackensack Meridian Health

The MeNTS method of prioritizing surgeries during the height of pandemic, developed by University of Chicago, helped procedures continue during time of need

Released: 17-Jun-2021 12:55 PM EDT
‘Nanodecoy’ Therapy Binds and Neutralizes SARS-CoV-2 Virus
North Carolina State University

Nanodecoys made from human lung spheroid cells (LSCs) can bind to and neutralize SARS-CoV-2, promoting viral clearance and reducing lung injury in a macaque model of COVID-19.

Newswise: Blood Cancer Patients with COVID-19 Fare Better with Convalescent Plasma
Released: 17-Jun-2021 11:55 AM EDT
Blood Cancer Patients with COVID-19 Fare Better with Convalescent Plasma
Washington University in St. Louis

A large, retrospective, multicenter study involving Washington University School of Medicine in St. Louis indicates that convalescent plasma from recovered COVID-19 patients can dramatically improve likelihood of survival among blood cancer patients hospitalized with the virus. The therapy involves transfusing plasma — the pale yellow liquid in blood that is rich in antibodies — from people who have recovered from COVID-19 into patients who have leukemia, lymphoma or other blood cancers and are hospitalized with the viral infection.

Released: 17-Jun-2021 11:05 AM EDT
Stress during pandemic linked to poor sleep
Washington State University

Many people likely lost sleep over COVID-19. A study of twins led by Washington State University researchers found that stress, anxiety and depression during the first few weeks of the pandemic were associated with less and lower quality sleep.

Newswise:Video Embedded university-of-miami-miller-school-study-shows-covid-19-mrna-vaccines-do-not-impact-male-fertility
VIDEO
Released: 17-Jun-2021 11:00 AM EDT
University of Miami Miller School Study Shows COVID-19 mRNA Vaccines Do Not Impact Male Fertility
University of Miami Health System, Miller School of Medicine

The Pfizer and Moderna mRNA COVID-19 vaccines is safe for male reproduction, according to a new study by University of Miami Miller School of Medicine researchers published in JAMA , the most widely circulated general medical journal in the world.


Showing results

1120 of 5853

close
2.73889